June 15, 2020

The Corporate Relationship Dept. BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Press Release

Please find enclosed press release for the audited financial results for the quarter and year ended March 31, 2020.

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair
Company Secretary

Encl: A/a
Pfizer Limited revenue from operations for the quarter and year ended March 31, 2020 is ₹502 crore and ₹2,152 crore respectively

Pfizer Limited announced its audited results for the quarter and year ended March 31, 2020.

**Revenues**

Revenue from operations for the quarter ended March 31, 2020 is ₹502 crore as compared to ₹536 crore in the same period last year.

Revenue from operations for the year ended March 31, 2020 is ₹2,152 crore as compared to ₹2,082 crore in the same period last year.

The current quarter sales have been impacted by divestiture of rights and interests in certain brands & COVID-19. Adjusting for the above, the growth for the quarter and year ended March 31, 2020 would have been 3.5% and 5.8% respectively.

**Profits before other income and tax**

Profit from operations (before other income and tax) for the quarter and year ended March 31, 2020 is ₹77 crore and ₹459 crore respectively.

**Profit after tax**

During the current quarter, the Company has reversed ₹44.5 crore pertaining prior years’ income tax provisions.

Net Profit after tax (including other comprehensive income) for the quarter ended March 31, 2020 is ₹98 crore as against ₹109 crore in the same period last year.

Net Profit after tax (including other comprehensive income) for the year ended March 31, 2020 is ₹500 crore as against ₹430 crore in the same period last year.

**Dividend**

The Board of Directors at its Meeting held on June 15, 2020, recommended a final dividend of ₹10 per equity share of ₹10 each (100%) for the financial year ended March 31, 2020.

It may further be noted that the Board of Directors at its Meeting held on April 27, 2020 had declared a special (interim) dividend of ₹320 per equity share of ₹10 each (3200%) for the financial year ended March 31, 2020 which was paid on May 19, 2020.

Both the above being events after the reporting date, in accordance with Ind AS 10, no adjustments have been made in the financial statements for the year ended 31 March 2020.
COVID-19 update

COVID-19, a pandemic caused by the novel Coronavirus, has emerged as an unprecedented challenge globally and to the pharmaceutical companies in particular, who have a responsibility towards public health. As a participant in this eco-system, the Company has taken a number of steps to respond to this unique situation. The Company has taken effective steps to ensure supply of essential medicines to its customers. The Company’s Goa Plant continues to remain operational at almost its usual capacity. The Company has strictly followed the protocols on social distancing and provided safe working environment at its Goa Plant.

There has been no significant adverse operational impact on the Company’s supply chain during March 2020 due to the Nationwide lockdown imposed by the Government of India in view of COVID-19, a pandemic caused by the Novel Coronavirus. The Company has monitored the impact of COVID-19 on all aspects of its business. The management has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment for impairment of goodwill, intangible assets, inventory based on the information available as on date, while preparing the financial results as of and for the year ended 31 March 2020.

In view of the continued uncertainties and its inability to predict the extend and duration of Covid-19 situation, the Company currently is unable to predict any future impact on its business operations. The Company will continue to ensure supply of essential medicines and take steps to mitigate any risks associated with Covid-19 pandemic.

For more information,

Investors: Prajeet Nair  Pfizer Limited
Ph : +91-9619929945
Email: prajeet.nair@pfizer.com

Media: Chikita Sobti  Pfizer Limited
+91-9820191347
chikita.sobti@pfizer.com

About Pfizer Limited:
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer
The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.